Literature DB >> 24357267

Thiamine-responsive megaloblastic anemia syndrome with Ebstein anomaly: a case report.

Mohammad Taghi Akbari1, Shohreh Zare Karizi, Reza Mirfakhraie, Bijan Keikhaei.   

Abstract

UNLABELLED: Thiamine-responsive megaloblastic anemia (TRMA) or Roger syndrome is a rare autosomal recessive disorder characterized by the occurrence of multiple clinical manifestations including megaloblastic anemia, diabetes mellitus, and sensorineural deafness. A few patients have been also described with congenital cardiac malformations. The patients usually respond to treatment with pharmacological doses of thiamine. Mutations in the SLC19A2 gene, located at chromosome 1q24.2, are responsible for this syndrome. Here, we present two new Iranian TRMA patients who were homozygous for c.697C > T mutation in the SLC19A2 gene. On follow-up, one of the patients showed Ebstein anomaly.
CONCLUSION: The present study confirms the variability of the clinical manifestations caused by the same mutation within patients with TRMA syndrome. Therefore, follow-up of the affected children should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24357267     DOI: 10.1007/s00431-013-2237-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Thiamine-responsive megaloblastic anemia syndrome with atrial standstill: a case report.

Authors:  Zehra Aycan; Veysel Nijat Baş; Semra Cetinkaya; Sebahat Yilmaz Ağladioğlu; Havva Nur Peltek Kendirci; Filiz Senocak
Journal:  J Pediatr Hematol Oncol       Date:  2011-03       Impact factor: 1.289

2.  Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families.

Authors:  Christopher J Ricketts; Jayne A Minton; Jacob Samuel; Indra Ariyawansa; Jerry K Wales; Ivan F Lo; Timothy G Barrett
Journal:  Acta Paediatr       Date:  2006-01       Impact factor: 2.299

3.  The spectrum of mutations, including four novel ones, in the thiamine-responsive megaloblastic anemia gene SLC19A2 of eight families.

Authors:  T Raz; V Labay; D Baron; R Szargel; Y Anbinder; T Barrett; W Rabl; M B Viana; H Mandel; A Baruchel; J M Cayuela; N Cohen
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

4.  Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness.

Authors:  V Labay; T Raz; D Baron; H Mandel; H Williams; T Barrett; R Szargel; L McDonald; A Shalata; K Nosaka; S Gregory; N Cohen
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

5.  Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome.

Authors:  G A Diaz; M Banikazemi; K Oishi; R J Desnick; B D Gelb
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

6.  Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update.

Authors:  Anke K Bergmann; Inderneel Sahai; Jill F Falcone; Judy Fleming; Adam Bagg; Caterina Borgna-Pignati; Robin Casey; Luca Fabris; Elizabeth Hexner; Lulu Mathews; Maria Leticia Ribeiro; Klaas J Wierenga; Ellis J Neufeld
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

7.  TRMA syndrome (thiamine-responsive megaloblastic anemia): a case report and review of the literature.

Authors:  Mehmet Akif Ozdemir; Mustafa Akcakus; Selim Kurtoglu; Tamer Gunes; Yasemin Altuner Torun
Journal:  Pediatr Diabetes       Date:  2002-12       Impact factor: 4.866

Review 8.  Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome.

Authors:  A Lorber; A Z Gazit; A Khoury; Y Schwartz; H Mandel
Journal:  Pediatr Cardiol       Date:  2003 Sep-Oct       Impact factor: 1.655

9.  Disruption of transport activity in a D93H mutant thiamine transporter 1, from a Rogers Syndrome family.

Authors:  Dana Baron; Yehuda G Assaraf; Stavit Drori; Ami Aronheim
Journal:  Eur J Biochem       Date:  2003-11

10.  Identification of a SLC19A2 nonsense mutation in Persian families with thiamine-responsive megaloblastic anemia.

Authors:  Aria Setoodeh; Amirreza Haghighi; Nasrollah Saleh-Gohari; Sian Ellard; Alireza Haghighi
Journal:  Gene       Date:  2013-02-20       Impact factor: 3.688

  10 in total
  1 in total

1.  A novel homozygous SLC19A2 mutation in a Portuguese patient with diabetes mellitus and thiamine-responsive megaloblastic anaemia.

Authors:  Sophia Tahir; Lieve Gj Leijssen; Maha Sherif; Carla Pereira; Anabela Morais; Khalid Hussain
Journal:  Int J Pediatr Endocrinol       Date:  2015-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.